CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

206356Orig1s000

PHARMACOLOGY REVIEW(S)
DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION

Application number: 206-356
Supporting document/s: 0010
Applicant's letter date: June 22, 2015
CDER stamp date: June 22, 2015
Product: ORFADIN (Nitisinone) Oral Suspension
Indication: For the treatment of hereditary tyrosinemia Type 1 (HT-1).
Applicant: Swedish Orphan Biovitrum AB (publ); US Agent-Quintiles, Inc.
Review Division: Division of Gastroenterology product (HFD-180)
Reviewer: Dinesh Gautam, Ph.D.
Supervisor/Team Leader: Sushanta Chakder, Ph.D.
Division Director: Donna Griebel, M.D.
Project Manager: Jessica Benjamin, M.P.H.

Disclaimer

Except as specifically identified, all data and information discussed below are necessary for approval of NDA 206-356, and are owned by Swedish Orphan Biovitrum AB (publ), or are data for which Swedish Orphan Biovitrum AB (publ) has obtained a written right of reference. Any information or data necessary for approval of NDA 206-356 that Swedish Orphan Biovitrum AB (publ) does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as described in the drug’s approved labeling. Any data or information described or referenced below from a previously approved application that Swedish Orphan Biovitrum AB (publ) does not own (or from FDA reviews or summaries of a previously approved application) is for descriptive purposes only and is not relied upon for approval of NDA 206-356.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXECUTIVE SUMMARY</td>
<td>3</td>
</tr>
<tr>
<td>1.1 RECOMMENDATIONS</td>
<td>3</td>
</tr>
<tr>
<td>1.2 BRIEF DISCUSSION OF NONCLINICAL FINDINGS</td>
<td>5</td>
</tr>
<tr>
<td>2 DRUG INFORMATION</td>
<td>6</td>
</tr>
<tr>
<td>3 STUDIES SUBMITTED</td>
<td>12</td>
</tr>
<tr>
<td>4 PHARMACOLOGY</td>
<td>12</td>
</tr>
<tr>
<td>5 PHARMACOKINETICS/ADME/TOXICOkinetics</td>
<td>12</td>
</tr>
<tr>
<td>6 GENERAL TOXICOLOGY</td>
<td>12</td>
</tr>
<tr>
<td>7 GENETIC TOXICOLOGY</td>
<td>12</td>
</tr>
<tr>
<td>8 CARCINOGENICITY</td>
<td>25</td>
</tr>
<tr>
<td>9 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY</td>
<td>25</td>
</tr>
<tr>
<td>10 SPECIAL TOXICOLOGY STUDIES</td>
<td>25</td>
</tr>
<tr>
<td>11 INTEGRATED SUMMARY AND SAFETY EVALUATION</td>
<td>25</td>
</tr>
<tr>
<td>12 APPENDIX/ATTACHMENTS</td>
<td>26</td>
</tr>
</tbody>
</table>
Executive Summary

1.1 Recommendations

1.1.1 Approvability
There are no pharm-tox approval issues.

1.1.2 Additional Non Clinical Recommendations
None

1.1.3 Labeling
The draft labeling of ORFADIN (Nitisinone) generally conforms to the format specified under 21CFR 201.57(c)(9)(i) through (c)(9)(iii) Requirements for PLLR (Pregnancy and Lactation Labeling Rule) Prescription Drug Labeling.

8.1 Pregnancy

Sponsor’s version:
**Evaluation:** The text should be modified as proposed below.

### 8.1 Pregnancy

**Risk Summary**

Limited data on nitisinone use in pregnant women are not sufficient to inform any drug associated risk. Animal reproduction studies have been conducted for nitisinone. In these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended human dose. In mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended human dose, and increased gestational length at doses 4 times the recommended human dose. In rabbits, nitisinone caused maternal toxicity and incomplete skeletal ossification of fetal bones at doses 1.6 times the recommended human dose [see Data].

The background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

**Animal Data**

#### 8.2 Reproduction studies have been performed in mice at oral doses of about 0.4, 4 and 20 times the recommended human dose (1 mg/kg/day) and in rabbits at oral doses of about 1.6, 4 and 8 times the recommended human dose based on the body surface area. In mice, nitisinone has been shown to cause incomplete skeletal ossification of fetal bones at 0.4, 4 and 20 times the recommended human dose, increased gestational length at 4 and 20 times the recommended human dose, and decreased pup survival at 0.4 times the recommended human dose based on the body surface area. In rabbits, nitisinone caused incomplete skeletal ossification of fetal bones at 1.6, 4 and 8 times the recommended human dose based on the body surface area.

### 13. NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**Sponsor’s version:**

Reference ID: 3899356
Evaluation: No changes are recommended in this section.

1.2 Brief Discussion of Nonclinical Findings

ORFADIN (nitisinone) Capsule was approved in 2002 (NDA 21-232) for the treatment of hereditary tyrosinemia type 1 (HT-1). The current NDA (206-356) is submitted for an oral suspension formulation of nitisinone, and the Applicant did not submit any new nonclinical studies of nitisinone. The new suspension formulation will make administration of nitisinone to infants and children easier. In this new oral suspension formulation, three degradation products, (b) (4) have been identified. The applicant assessed the genotoxic potential of these impurities using QSAR analysis, and in vitro and in vivo genotoxicity assays.

The Applicant assessed the genotoxic potential of (b) (4) and (b) (4) through a computational toxicology based assessment using Quantitative Structure-Activity Relationship (QSAR) analysis. Furthermore, bacterial reverse mutation tests were performed to determine the genotoxicity potential of (b) (4) and (b) (4) was also assessed for genotoxic potential using an in vivo combined micronucleus and alkaline Comet assay in mice. QSAR analysis showed no mutagenic potential of (b) (4) in the bacterial reverse mutation assay, and (b) (4) was considered to be a non-genotoxic impurity. QSAR analysis predicted (b) (4) to be genotoxic and mutagenic in a bacterial reverse mutation (Ames) test. When (b) (4) was subjected to the in vitro bacterial reverse mutation test, weak mutagenic responses were observed both in the absence and in the presence of metabolic activation. However, (b) (4) tested negative in the nitro-reductase deficient TA100NR strain in the Ames test, implicating nitrreduction as the crucial factor of bacterial mutagenicity of (b) (4). The same functional group is present in the parent compound (nitisinone) which is also predicted to be mutagenic. Nitisinone was not positive in the bacterial reverse mutation assay and is regarded as a non-mutagen. The genotoxicity of (b) (4) was further investigated in vivo in the mouse bone marrow micronucleus assay and the Comet assay. Administration of (b) (4) resulted in increased frequencies of micronucleated polychromatic erythrocytes (PCE) in the bone marrow of mice at mid (700 mg/kg/day) and high (1400 mg/kg/day) doses. In the low dose group (350 mg/kg/day) the frequency of micronucleated PCE was not elevated. Despite the observed clastogenic effect of (b) (4) treatment in the bone marrow, no DNA damage could be detected with the Comet assay in the duodenum, liver or blood cells. A fluorescence in situ hybridization (FISH)-analysis of the induced micronuclei revealed that the chromosomal lesions were mediated by a clastogenic mechanism, i.e. the majority of the induced micronuclei were centromere-negative. Although, (b) (4) was found to have a genotoxic potential, based on the fact that nitisinone itself has positive genotoxicity findings, the presence of the
impurity would not add additional risk for cancer (ICH M7). The Guidance also recommends that these “impurities could be controlled at acceptable levels for non-mutagenic impurities”. In genotoxicity studies with nitisinone, it was negative in the Ames test and the in vivo mouse liver unscheduled DNA synthesis (UDS) test. Nitisinone was positive in the mouse lymphoma cell (L5178Y/TK^+^) forward mutation test and in an in vivo mouse bone marrow micronucleus test.

A fertility study of Nitisinone was conducted in male and female mice at oral dose of 5, 50 and 250 mg/kg/day. Male mice were administered 4 weeks prior to mating through the mating period and female mice were treated 2 weeks prior to mating through gestation Day 7. An increased pre-coital interval was noticed in females in the ≥50 mg/kg/day dose groups and an increased post-implantation loss was seen in the 250 mg/kg/day dose group.

In an embryofetal development study in mice, nitisinone was administered orally to pregnant mice at doses of 5, 50, 250 mg/kg/day from gestation Day 7 through 16. There was incomplete skeletal ossification of fetal bones at doses of ≥5mg/kg/day. The pregnant mice that received ≥ 50 mg/kg/day exhibited an increased gestation length, and pup survival rate decreased by 9% compared to 5% in the untreated control. In an embryofetal development study in rabbits, nitisinone was administered orally to the pregnant animals at doses of 5, 12 and 25 mg/kg/day from gestation Day 7 through 19. Maternal toxicity and incomplete skeletal ossification of fetal bones were observed at all doses (≥ 5 mg/kg/day).

2 Drug Information

2.1 Drug: ORFADIN (Nitisinone) oral suspension.

2.1.1 CAS Registry Number (Optional)
104206-65-7

2.1.2 Generic Name
Nitisinone

2.1.3 Code Name
None

2.1.4 Chemical Name
2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione.

2.1.5 Molecular Formula/Molecular Weight
C_{14}H_{10}F_{3}NO_{5} / 329.23

2.1.6 Structure
2.1.7 Pharmacologic class

Enzyme (hydroxyphenyl-pyruvate dioxygenase or HPPD) inhibitor.

2.2 Relevant IND/s, NDA/s, and DMF/s


2.3 Clinical Formulation

2.3.1 Drug Formulation

The drug product is supplied in a brown 100 mL medicinal glass Type III bottle sealed with a child resistant cap. Each bottle contains 90 mL of suspension. The composition of the drug product is shown in the Applicant’s Table below.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Quantity (mg)</th>
<th>Function</th>
<th>Reference to standards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitisinone</td>
<td>4.0</td>
<td>Active substance</td>
<td>In-house specification</td>
</tr>
<tr>
<td>Hydroxypropyl methylcellulose (HPMC)</td>
<td></td>
<td></td>
<td>Ph. Eur./NF</td>
</tr>
<tr>
<td>Glycerol</td>
<td></td>
<td></td>
<td>Ph. Eur./USP</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td></td>
<td></td>
<td>Ph. Eur./NF</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td></td>
<td></td>
<td>Ph. Eur./NF</td>
</tr>
<tr>
<td>Citric acid monohydrate</td>
<td></td>
<td></td>
<td>Ph. Eur./USP</td>
</tr>
<tr>
<td>Trisodium citrate dihydrate</td>
<td></td>
<td></td>
<td>Ph. Eur./USP</td>
</tr>
<tr>
<td>Strawberry aroma</td>
<td></td>
<td></td>
<td>In-house specification</td>
</tr>
<tr>
<td>Water, purified</td>
<td></td>
<td></td>
<td>Ph. Eur./USP</td>
</tr>
</tbody>
</table>

2.3.2 Comments on Novel Excipients

No novel excipients were used in the formulation of the drug product.

2.3.3 Comments on Impurities/Degradants of Concern

The known impurities that are tested as part of the Nitisinone oral suspension can be classified into three categories: organic impurities, inorganic . The known process related impurities are presented in the Table below.
Organic impurities are from Inorganic impurities are controlled and are not more than from as per the USP <221> that could be potentially present in the, was routinely evaluated by a validated GC method. Based on ICH Q3C (R4) guidance, these impurities are within the acceptable limits.
Potential primary and secondary degradation products of nitisinone in Orfadin oral suspension are shown in the Applicant’s Table below.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Chemical name</th>
<th>Molecular mass (g/mole)</th>
<th>Molecular formula</th>
<th>Structural formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary degradation products:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(4) is a known impurity/degradation product in the drug substance as well as in the currently approved solid oral dosage form. (4) and (4) are the main degradation products of nitisinone in Orfadin oral suspension. The stability studies showed the level of (4) are below the reporting limit corresponding to...
Stability testing of the suspension has revealed two new degradation products in Orfadin oral suspension, the environment of the formulation. In the 9-month stability study, the total amount of the

The stability specification used for the drug product (ORFADIN) is shown in the Applicant’s Table below.

<table>
<thead>
<tr>
<th>Test</th>
<th>Method</th>
<th>Acceptance Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Visual inspection</td>
<td>White slightly viscous opaque suspension</td>
</tr>
<tr>
<td>Related substances, % of labeled amount</td>
<td></td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Any unspecified</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>USP &lt;791&gt;</td>
<td></td>
</tr>
<tr>
<td>Particle size distribution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D&lt;sub&gt;100&lt;/sub&gt;, lam</td>
<td></td>
<td>For information</td>
</tr>
<tr>
<td>D&lt;sub&gt;50&lt;/sub&gt;, lam</td>
<td></td>
<td>For information</td>
</tr>
<tr>
<td>D&lt;sub&gt;30&lt;/sub&gt;, lam</td>
<td></td>
<td>For information</td>
</tr>
<tr>
<td>Sodium benzoate, % of labeled amount</td>
<td></td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Reconstitutability, % of labeled amount&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Ph. Eur. 2.9.27 (b) (4)</td>
<td></td>
</tr>
<tr>
<td>Uniformity of mass of delivered doses from containers</td>
<td>Ph. Eur. 2.9.27</td>
<td>To comply</td>
</tr>
<tr>
<td>Assay, % of labeled amount</td>
<td></td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Dissolution after 1(h) minutes, Q&lt;sup&gt;3&lt;/sup&gt; from LC</td>
<td>USP &lt;711&gt; (b) (4)</td>
<td>To comply</td>
</tr>
<tr>
<td>Microbiological quality</td>
<td>USP &lt;61&gt;</td>
<td></td>
</tr>
<tr>
<td>TANC, CFU/mL</td>
<td>NMT (4)</td>
<td></td>
</tr>
<tr>
<td>TYMC, CFU/mL</td>
<td>NMT (4)</td>
<td></td>
</tr>
<tr>
<td>Specified microorganisms</td>
<td>USP &lt;62&gt;</td>
<td></td>
</tr>
<tr>
<td>Antimicrobial effectiveness testing</td>
<td>USP &lt;51&gt;</td>
<td>Complies (b) (4)</td>
</tr>
</tbody>
</table>

<sup>1</sup>The acceptance criterion corresponds to the total amount of

Reference ID: 3899356
In the QSAR analysis, was predicted negative for mutagenicity. However, was predicted positive. was identified as a weak bacterial mutagen in Ames test. However, tested negative in the nitro-reductase deficient TA100NR strain. In in vivo micronucleus assay, induced an increase in micronucleated polychromatic erythrocytes of the bone marrow of mice, most likely via a clastogenic mechanism. Despite the observed clastogenic effect of treatment in the bone marrow, no DNA damage could be detected with the Comet assay in duodenum, liver or blood cell tissues. In addition, the parent compound itself is genotoxic. Thus, an acceptable intake of was calculated based on a permitted daily exposure (PDE) by the applicant.

The PDE for was calculated to be μg/day (details of calculation are shown below).

\[
PDE = \frac{NOAEL}{(F1 \times F2 \times F3 \times F4 \times F5 \times \text{adjustment factor}^* )}
\]

- \( F1 = 5 \) (rat-to-human)
- \( F2 = 10 \) (account for human variability between individuals)
- \( F3 = 1 \) (results from chronic life-time study)
- \( F4 = 10 \) (severe toxicity, i.e. non-genotoxic carcinogenicity)
- \( F5 = 1 \) (NOAEL established)

*Adjustment factor of 10 for exposures before 2 years of age and an adjustment factor of 3 for exposures between 2 and less than 16 years of age. The adjustment factor for adults is 1 (FDA guidance for genotoxicity and carcinogenicity impurities 2008).

NOAEL of was μg/day adopted from in vivo mouse bone marrow micronucleus assay.

\[
PDE = \frac{\text{mg/kg/day}}{(5 \times 10 \times 1 \times 10 \times 1 \times 1)} = \text{ug/day}
\]

The anticipated daily intake of total amount of will be ug/day kg body weight patient. Thus, the anticipated daily intake of from Orfadin oral suspension is much lower than the calculated PDE and is within acceptable limits.

### 2.4 Proposed Clinical Population and Dosing Regimen

Orfadin (Nitisinone) oral suspension is indicated for the treatment of hereditary tyrosinemia type 1 (HT-1). The recommended dose is 1 mg/kg/day divided into 2 daily doses followed by maximum dose of 2 mg/kg/day. One mL oral suspension contains 4 mg nitisinone.

### 2.5 Regulatory Background

A Type B pre-NDA teleconference was held on July 9, 2013 regarding new oral suspension formulation of Orfadin.
3 Studies Submitted
1. Nitisinone: Potential Genotoxic Degradants Risk Assessment Report evaluated by the QSAR analysis, using Derek Nexus 2.0 and Leadscope models (Study # TKT-2013-007).
2. Bacterial Reverse Mutation Assay (Study # UJP0002).
3. Bacterial Reverse Mutation Assay (Study # 8302339).
4. Mouse micronucleus and alkaline comet assay (Study # 8302340).

3.1 Studies Reviewed
All studies mentioned in section 3.0 were reviewed.

3.2 Studies Not Reviewed
None

3.3 Previous Reviews Referenced
None.

4 Pharmacology
The applicant did not submit any pharmacology studies of Nitisinone.

5 Pharmacokinetics/ADME/Toxicokinetics
The applicant did not submit any pharmacokinetic studies with Nitisinone.

6 General Toxicology
No single- or repeated-dose toxicology study reports were submitted.

7 Genetic Toxicology
No genetic toxicology studies of nitisinone were submitted in this NDA. The proposed oral suspension formulation revealed the presence of two novel degradation products following storage, i.e.

[Reference ID: 3899356]
analysis (Section 7.4). Furthermore, the applicant has performed genotoxicity studies of (b) (4) and (b) (4) to support a hazard assessment of the impurity. Genotoxicity studies of these impurities are reviewed below.

7.1  **In Vitro Reverse Mutation Assay in Bacterial Cells (Ames)**

**Study title:** (b) (4)  **Bacterial Reverse Mutation Test**

<table>
<thead>
<tr>
<th>Study no.</th>
<th>UJP0001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study report location</td>
<td>Electronic submission</td>
</tr>
<tr>
<td>Conducting laboratory and location</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Date of study initiation</td>
<td>March 5, 2014</td>
</tr>
<tr>
<td>GLP compliance</td>
<td>No</td>
</tr>
<tr>
<td>QA statement</td>
<td>No</td>
</tr>
<tr>
<td>Drug, lot #, and % purity</td>
<td>Lot # P094HH2, purity (b) (4)%; lot # P114AS2, purity (b) (4) %</td>
</tr>
</tbody>
</table>

**Key Study Findings**

Bacterial reverse mutation assays were conducted in *Salmonella typhimurium* (TA1537, TA1535, TA100, TA98) and *Escherichia coli* (WP2uvrA) with (b) (4) at concentrations of 50-5,000 µg/plate in the presence or absence of metabolic activation. (b) (4) showed mutagenic potential in the bacterial reverse mutation test for the tester strain TA100 in the presence and absence of S-9 mix, under plate incorporation conditions.
Methods

Strains: *Salmonella typhimurium* strains: TA1537, TA1535, TA100, TA98 and *E. coli* WP2uvrA

Concentrations in definitive study: 50, 150, 500, 1500 or 5000 μg/plate. Under plate incorporation conditions, the concentrations were 500, 1500, 2500, 3500 or 5000 μg/plate for TA100 in the presence of S-9 mix.

Basis of concentration selection: A dose range finding study to determine the toxicity of was carried out using TA98 and WP2uvrA strains in the presence and absence of S-9 mix. The dose levels were 1.5, 5, 15, 50, 150, 500, 1500 or 5000 μg/plate.

Negative control: Dimethyl sulfoxide (DMSO)

Positive control: 4-Nitroquinoline-N-oxide (4NQO), 9-aminoacridine (9AA), 2-nitrofluorene (2NF), 2-aminoanthracene (2AA) and Sodium Azide (SA).

Formulation/Vehicle: DMSO

Incubation & sampling time: Plates were incubated at 37°C for approximately 48 h for all strains in the presence or absence of metabolic activation (S9).

Study Validity

The study was validated by the incidence of spontaneous revertants in the solvent controls within the range of historical values. A test was considered to be positive if the test item induced dose-related statistically significant increases in numbers of revertants compared with negative controls scored. A test was considered to be negative if the test item produced no greater increases in revertants for any strain.

Results

Batch P094HH2 showed a dose-related statistically significant increase in revertant numbers for TA100 at 500, 1500 and 5000 μg/plate in the absence of S-9 mix. There was a statistically significant increase in revertant numbers for TA100 at 5000 μg/plate in the presence of S-9 mix, which was outside of the laboratory historical background range. However, there were no dose-related or statistically significant increases in revertant numbers observed for any other strain at any dose of batch P094HH2, in the presence or absence of S-9 mix, under plate incorporation conditions. Data is presented in the Applicant’s Table below.
Another experiment was conducted with TA100 strain only in the presence of S-9 mix using the plate incorporation method, in order to further investigate the potential positive response observed in the above experiment. The result showed that there was a dose-related statistically significant increase in the revertant numbers in TA100 at 3500 and 5000 μg/plate in the presence of S-9 mix, which were outside of the laboratory historical background range. Data is presented in the Applicant’s Table below.
In another study, a batch of (P114AS2) with high purity ( %) was tested in TA100 in the presence and absence of S-9 mix. The result showed that there was a dose-related statistically significant increase in revertant numbers for TA100 at 1500 and 5000 μg/plate in the absence of S-9 mix. There was a statistically significant increase in revertant numbers at 5000 μg/plate in the presence of S-9 mix. In both cases, the increase at 5000 μg/plate was outside of the laboratory historical background range. Data are presented in the Applicant’s Table below.

### Table 2 - Mean Number of Revertants Per Plate - Experiment 2 Batch P094HH2- Plate Incorporation

<table>
<thead>
<tr>
<th>Strain</th>
<th>% S-9 mix v/v</th>
<th>Dose level of test item (μg/plate)</th>
<th>PC</th>
</tr>
</thead>
<tbody>
<tr>
<td>TA100</td>
<td>10</td>
<td>0  159.7  187.3  229.3  238.3  314.0*  323.0*  2680.0</td>
<td></td>
</tr>
</tbody>
</table>

* = p < 0.01

PC: positive control

### Table 3 - Mean Number of Revertants Per Plate - Experiment 3 Batch P114AS2- Plate Incorporation

<table>
<thead>
<tr>
<th>Strain</th>
<th>% S-9 mix v/v</th>
<th>Dose level of test item (μg/plate)</th>
<th>PC</th>
</tr>
</thead>
<tbody>
<tr>
<td>TA100</td>
<td>0</td>
<td>0  145.7  145.3  166.0  188.0  234.7*  294.3*  786.0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strain</th>
<th>% S-9 mix v/v</th>
<th>Dose level of test item (μg/plate)</th>
<th>PC</th>
</tr>
</thead>
<tbody>
<tr>
<td>TA100</td>
<td>10</td>
<td>0  178.7  193.3  187.3  220.7  219.0  346.7*  3287.0</td>
<td></td>
</tr>
</tbody>
</table>

* = p < 0.01

PC: positive control

**Study title:** **Bacterial Reverse Mutation Assay**

- **Study no.:** 8302339
- **Study report location:** Electronic submission
- **Conducting laboratory and location:**
- **Date of study initiation:** May 9, 2014
- **GLP compliance:** Yes
- **QA statement:** Yes
- **Drug, lot #, and % purity:** Lot # P142AS2-P5, purity %

**Key Study Findings**

To exclude the possibility of nitro reductase (NR) involvement in the activation of the bacterial reverse mutation was tested in NR deficient strain TA100.
(b) (4) was used at concentrations of 5-5,000 µg/plate in the presence or absence of metabolic activation. In this test, (b) (4) tested clearly negative in the nitro-reductase (NR) deficient TA100NR strain, indicating that the bacterial nitro-reductase is crucial for the activation of (b) (4) to a DNA-reactive species.

Methods

Strains: Salmonella typhimurium strains: TA100 and TA100NR
Concentrations in definitive study: 5, 16, 50, 160, 500, 1600 or 5000 µg/plate.
Basis of concentration selection: A dose range finding study to determine the toxicity of (b) (4)
Negative control: Dimethyl sulfoxide (DMSO)
Positive control: Sodium Azide (SA) and Metronidazole (MTZ).
Formulation/Vehicle: DMSO
Incubation & sampling time: Plates were incubated at 37°C for approximately 48 h for all strains in the presence or absence of metabolic activation (S9).

Study Validity

The study was validated by the incidence of spontaneous revertants in the solvent and positive controls within the range of historical values, and the assay results were evaluated as positive if the number of revertant colonies in the groups treated with the test substance was at least twice the number in the group treated with the solvent (that is, at least twice the number of spontaneous revertant colonies) and if this increase in the number of revertant colonies was found to be concentration-dependent.

Results

(b) (4) was negative in the Ames test for the nitro-reductase (NR) deficient TA100NR strain, indicating that the bacterial nitro-reductase is crucial for the activation of (b) (4) to a DNA-reactive species. The Applicant did not provide the study data in the study report.

Study title: (b) (4) Bacterial Reverse Mutation Test

Study no.: UJP0002
Study report location: Electronic submission
Conducting laboratory and location: (b) (4)
Date of study initiation: March 5, 2014
GLP compliance: No
QA statement: No
Drug, lot #, and % purity: Lot # F173AS1, purity (b) (4)%; lot # P094HHI, purity (b) (4)%;
Key Study Findings
In the bacterial reverse mutation assays in *Salmonella typhimurium* and *Escherichia coli*, at concentrations of 1.5-5,000 µg/plate did not induce gene mutation with or without metabolic activation.

Methods

Strains: *Salmonella typhimurium* strains: TA1535, TA1537, TA100, TA98 and *E. coli* WP2uvrA

Concentrations in definitive study: 1.5, 5, 15, 50, 150, 500, 1500 or 5000 µg/plate.

Basis of concentration selection: The doses selected for the mutation test were based on testing up to the regulatory maximum dose level of 5000 µg/plate.

Negative control: Dimethyl sulfoxide (DMSO)

Positive control: 4-Nitroquinoline-N-oxide (4NQO), 9-aminoacridine (9AA), 2-nitrofluorene (2NF), 2-aminoanthracene (2AA) and Sodium Azide (SA).

Formulation/Vehicle: DMSO

Incubation & sampling time: Plates were incubated at 37°C for approximately 48 h for all strains in the presence or absence of metabolic activation (S9).

Study Validity
The study was validated by the incidence of spontaneous revertants in the solvent controls within the range of historical values, and the significant increase in numbers of revertant colonies in the positive control articles. All necessary criteria for a valid study, including appropriate phenotypic confirmations and vehicle/positive control response were fulfilled.

Results
There were no dose-related or statistically significant increases in revertant numbers observed in any strain at any dose of (b)(4) in the presence or absence of S-9 mix, under plate incorporation conditions. Data are presented in the applicant’s Table below.
### Table 1 - Mean Number of Revertants Per Plate - Plate Incorporation

<table>
<thead>
<tr>
<th>Strain</th>
<th>% S-9 mix v/v</th>
<th>Dose level of test item (µg/plate)</th>
<th>PC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>50</td>
</tr>
<tr>
<td>TA1535</td>
<td>0</td>
<td>12.3</td>
<td>14.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>15.0</td>
</tr>
<tr>
<td>TA98</td>
<td>0</td>
<td>39.7</td>
<td>45.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>176.0</td>
</tr>
<tr>
<td>WP2uvrA</td>
<td>0</td>
<td>36.7</td>
<td>32.7</td>
</tr>
</tbody>
</table>

**PC:** positive control  
**ppt:** compound precipitation  
**srl:** slightly reduced background bacterial lawn
7.3  *In Vivo* Clastogenicity Assay in Rodent (Micronucleus Assay)

**Study title:** Mouse Micronucleus and Alkaline Comet Assay.

- **Study no:** 8302340
- **Study report location:** Electronic submission
- **Conducting laboratory and location:**
- **Date of study initiation:** May 1, 2014
- **GLP compliance:** Yes
- **QA statement:** Yes
- **Drug, lot #, and % purity:** Batch # P142AS2-P5; purity: %

**Key Study Findings**

In the *in vivo* micronucleus and Comet assays, was administered orally (gavage) for 3 days at doses of 350, 700 and 1400 mg/kg/day to male Crl:CD-1 (ICR) mice. induced an increase in micronucleated polychromatic erythrocytes of the bone marrow of male mice at doses of 700 and 1400 mg/kg/day. In the same animals did not induce DNA damage in the liver, duodenum or blood cells when dosed up to 1400 mg/kg/day, as analyzed by the Comet assay.

**Methods**

- **Doses in definitive study:** 350, 700 and 1400 mg/kg/day
- **Frequency of dosing:** Once daily for 3 days
- **Route of administration:** Oral gavage
- **Dose volume:** 14 mL/kg for groups and 10 mL/kg for positive control.
- **Formulation/Vehicle:** 7.5 mg/mL carboxymethyl cellulose, 1 mg/mL Tween 80 in 50 mM citrate buffer.
- **Species/Strain:** Crl:CD-1 (ICR) mice.
- **Number/Sex/Group:** 6 males/group and 3 for positive control
- **Satellite groups:** None
- **Basis of dose selection:** The highest dose was selected from the dose range finding study based on maximum tolerated dose.

- **Negative control:** Vehicle
- **Positive control:** Cyclophosphamide (CPA) 40 mg/kg, single oral administration dosed at 24 hours, sampled at 48 hours (Micronucleus End Point).

  Ethyl methanesulfonate (EMS) 150 mg/kg, single oral administration dosed at 45 hours, sampled at 48 hours (Comet End Point).

**Study Validity**

The vehicle control data were generally comparable with the laboratory’s historical vehicle control data. The positive control treatment (cyclophosphamide) resulted in a
statistically significant increase in group mean micronucleated polychromatic erythrocytes (MNPCE) over the concurrent vehicle control response. Thus, the micronucleus assay is accepted as a valid assay.

The vehicle control data for liver and blood were generally comparable with the laboratory’s historical vehicle control data. The vehicle control group mean and individual animal data for duodenum were outside the historical vehicle control data ranges. However, there were limited historical vehicle control data in mice as a comparator. The data were subsequently compared to rat historical vehicle control data ranges and were found to be well within range. Therefore, the data were deemed acceptable. The positive control Ethyl methanesulfonate (EMS) induced a marked increase in Comet parameters in all tissues compared to the concurrent vehicle control. Thus, the Comet assay was considered to be valid.

Results
Mice treated with exhibited group mean percentage of polychromatic erythrocytes (PCE) values that were similar to the concurrent vehicle control group and which were generally comparable with the laboratory’s historical control data. There was no evidence of any test article-induced toxicity to the bone marrow (as would usually be indicated by a notable decrease in %PCE values compared to the vehicle control group or dose dependent decrease). Following the initial scoring of 2000 PCE, there were statistically significant, dose related increases in the number of mean micronucleated polychromatic erythrocytes (MNPCE) at 700 and 1400 mg/kg/day compared to vehicle control mean MNPCE count. It was therefore decided to score the same slides again to determine the MNPCE count over 4000 PCE. Following the repeat analysis, animals displayed inter-group heterogeneity at the intermediate and high doses of 700 and 1400 mg/kg/day. Therefore the percentages of MNPCE in each treated group were compared with vehicle control. Treatment of mice with induced statistically significant (p≤0.05) increases in mean MNPCE frequencies compared to the vehicle control at 700 and 1400 mg/kg/day. There was also a statistically significant linear trend (p≤0.01) indicating a dose response. The range of individual MNPCE frequencies for animals dosed at 700 and 1400 mg/kg/day were mainly either at the top end or exceeded the laboratory’s historical control distribution, and the group mean percentage of MNPCE at 700 and 1400 mg/kg/day were more than 2-fold higher than the concurrent vehicle control group and exceeded the 95% historical vehicle control reference range. The low dose of 350 mg/kg/day induced group mean MNPCE frequencies were not statistically different from the concurrent vehicle control and all of these animals were considered to fall within the laboratory’s historical control MNPCE distribution. Data are presented in the Applicant’s Table below.
Thus, induced micronuclei in the polychromatic erythrocytes of the bone marrow in male mice treated at 700 and 1400 mg/kg/day.

The Comet assay of liver, duodenum and blood showed that there was no dose-related increase in percentage clouds cells following treatment with Thus the result showed that treatment with did not cause excessive DNA damage that could have interfered with Comet analysis. Group mean percentage of tail intensity and tail moment values for all groups of animals treated with (all tissues) were generally comparable with the concurrent group mean vehicle control data. All individual animal data at all dose levels were generally consistent with the concurrent vehicle control animals and generally fell within the laboratory’s historical control. These data confirm that did not induce DNA damage in the liver, duodenum or blood cells of treated male mice. Data are presented in the Applicant’s Tables below.
7.4 Other Genetic Toxicity Studies

The Applicant has submitted a report on the potential genotoxicity of Nitisinone and their impurities, which are evaluated by the QSAR analysis (Derek Nexus and Leadscope model).

**Study: Nitisinone: Potential Genotoxic Degradants Risk Assessment Report (TKT-2013-007).**

**Method:** The potential bacterial mutagenesis of nitisinone and their degradant (listed in the Applicant’s table below) were predicted by two Quantitative Structure-Activity Relationship (QSAR) prediction methodologies. They are Derek Nexus (Lhasa Ltd., version 3.0.1, knowledge base Derek KB 2012 1.0) and Leadscope Model Applier (Leadscope Inc., version 1.6.0-17).
**Results:** The Derek Nexus and Leadscope Model predicted that both [compounds] are positive for bacterial mutagenicity. Positive for mutagenesis was originated from the aromatic nitro function, which is similar to nitisinone. However, nitisinone was negative in Ames test (ORFADINE, Nitisinone, 2002). Thus, the Applicant concluded that [compounds] are not likely to possess a potential for bacterial mutagenicity and considered as a non-genotoxic degradants. These degradants are NMT [threshold]% in the drug product, and meet the thresholds qualification according to ICH Q3B guidelines.

Both Derek Nexus and Leadscope Model predicted non-genotoxic for [compounds]. Furthermore, in the Nitisinone drug product it is NMT [threshold]% and meet the thresholds qualification according to ICH Q3B guidelines.

The Derek Nexus Model predicted negative for bacterial mutagenicity for [compound], but Leadscope Model predicted positive for mutagenicity in the Microbial Mut model., in the drug product and considered as not mutagenic and meet the thresholds qualification according to ICH Q3B guidelines.
The safety evaluation of (b)(4) is calculated based on the PDE (Permitted Daily Exposure). The highest level of (b)(4) was NMT % in oral suspension. The anticipated maximum exposure to (b)(4) would be (b)(4) µg/day based on the maximum daily administration of (body weight). (b)(4) is negative in the bacterial mutagenicity (Ames) test. (b)(4) is not mutagenic and in a 2-year combined chronic toxicity/carcinogenicity study in rats, the no-observed-effect level (NOEL) of (mg/kg/day) (b)(4).

The PDE for (b)(4) was calculated to be (µg/day) (details of calculation are shown below) which is much higher than the anticipated maximum daily intake of (µg/day). Therefore, there is a reasonable assurance of safety for the (b)(4) in nitisinone oral suspension.

\[
PDE = \frac{\text{NOEL}}{(F1 \times F2 \times F3 \times F4 \times F5 \times \text{adjustment factor}^*)}
\]

- \(F1=5\) (rat-to-human)
- \(F2=10\) (account for human variability between individuals)
- \(F3=1\) (results from chronic life-time study)
- \(F4=10\) (severe toxicity, i.e. non-genotoxic carcinogenicity)
- \(F5=1\) (NOAEL established)

PDE of (µg/day).

8  Carcinogenicity

No carcinogenicity studies were submitted.

9  Reproductive and Developmental Toxicology

No reproductive and developmental toxicology studies were submitted.

10 Special Toxicology Studies

No special toxicology studies were submitted.

11 Integrated Summary and Safety Evaluation

In the current submission, the applicant is seeking approval of nitisinone oral suspension for the treatment of hereditary tyrosinemia type 1 (HT-1). Orfadin capsules have been approved in USA in 2002 for the treatment of hereditary tyrosinemia type 1 (HT-1) under NDA 21-232.
The recommended maximum oral daily dose is 2 mg/kg/day divided into two daily doses.

In this 505 (b)(1) NDA, the applicant relied on the Agency’s previous assessment of safety of nitisinone. In the current suspension formulation, the Applicant identified three degradation products, (b) (4) have been identified. Among them, (b) (4) is a known impurity/degradation product in the drug substance as well as in the current solid oral dosage form. The potential genotoxicity profiles of these compounds were determined by QSAR analysis and AMES tests. (b) (4) was further investigated in vivo in mice using bone marrow micronucleus assay and the Comet assay. (b) (4) was negative in QSAR and Ames test. However, (b) (4) was determined to be positive in QSAR analysis, AMES test and bone marrow micronucleus assay. But (b) (4) was negative in the nitro-reductase deficient TA100NR strain in Ames test and no DNA damage could be detected with the Comet assay in duodenum, liver or blood cell tissue. (b) (4) contains the same functional group as parent compound (nitisinone), which is also predicted to be mutagenic in the mouse lymphoma cell (L5178Y/TK^+/−) forward mutation test and in an in vivo mouse bone marrow micronucleus test. According to ICH M7 guidance (2015), if the drug substance itself is mutagenic, exposure to a mutagenic impurity in these cases would not significantly add to the cancer risk of the drug substance. The Guidance also recommends that these “impurities could be controlled at acceptable levels for non-mutagenic impurities”. Thus, there are no safety concerns for the impurities/degradants in the drug product, and no pharm-tox related safety issues were identified for ORFADIN (nitisinone) oral suspension.

12 Appendix/Attachments: None
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DINESH C GAUTAM
03/09/2016

SUSHANTA K CHAKDER
03/09/2016